Auro Laboratories Limited

BSE: 530233
Auro Laboratories Limited - pharma in Thane, Maharashtra, India. FY 2026 financials and compliance.
CIN L33125MH1989PLC051910 Incorporated 26 May 1989 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - BSE: 530233 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹30.74 Cr
▲ 58.47% YoY
EBITDA · FY 2026
₹12.02 Cr
▲ 195.98% YoY
Net profit · FY 2026
₹3.53 Cr
▲ 92.13% YoY
Authorised capital
₹7 Cr
Registered with MCA
Paid-up capital
₹6.23 Cr
Issued & subscribed
Open charges
₹68 Cr
Satisfied ₹11.97 Cr
Company age
37 yrs
Est. 1989
Last financials
Mar 2025
Balance sheet date

About Auro Laboratories Limited

Data last updated: 24 December 2025

Auro Laboratories Limited is a public limited company based in Thane, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 26 May 1989, the company has been in operation for over 37 years.

Registered with ROC Mumbai under CIN L33125MH1989PLC051910. Listed on BSE: 530233.

Capital: an authorised share capital of ₹7 Cr and a paid-up capital of ₹6.23 Cr. It is led by directors including Kiran Suresh Kulkarni and Mahendra Kumar Daga.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: K – 56 M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506.

As per the financials filed for FY 2025, the company reported a revenue of ₹20.05 Cr, a decline of 64% compared to the previous year.

The company is associated with 2 brands - Auro Laboratories, Aurolab. As per MCA filings, the company has open charges of ₹68 Cr and satisfied charges of ₹11.97 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurolabs.com.

Company Details of Auro Laboratories Limited
CIN L33125MH1989PLC051910
Registration Number 051910
Incorporation Date 26 May 1989
ROC Mumbai
Listing Status Listed (BSE: 530233)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sharat Deorah Managing Director Kiran Suresh Kulkarni Whole-Time Director Siddhartha Deorah Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    aurolabs.com
  • Social Media
    **************
  • Registered Address
    K – 56 M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506
  • Industry
    Pharma, API Manufacturers
Company report
Auro Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Auro Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Auro Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Auro Laboratories Limited

Auro Laboratories Limited has one previous CIN (Corporate Identification Number): U33125MH1989PLC051910. The current CIN is L33125MH1989PLC051910, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L33125MH1989PLC051910 Current
U33125MH1989PLC051910 Previous

Associated Brands with Auro Laboratories Limited

Auro Laboratories Limited operates two associated brands: Auro Laboratories and Aurolab. These brands represent Auro Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Auro Laboratories
Active pharmaceutical ingredients and intermediates are manufactured for pharmaceutical applications. aurolabs.com
Aurolab
Manufacturer of high quality ophthalmic consumables aurolab.com

Competitors & Alternatives of Auro Laboratories Limited

Brands and companies operating in the same space as Auro Laboratories Limited include Laurus Labs, Bausch & Lomb, Symbiotec and 7 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Bausch & Lomb Bausch & Lomb Ophthalmic pharmaceuticals and instruments are developed for eye care. Bridgewater, United States, United States 1853
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Appasamy Associates Appasamy Associates Ophthalmic instruments and pharmaceutical products are developed for eye care. Chennai, India, India 1978

Business Activity of Auro Laboratories Limited

Auro Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Auro Laboratories Limited

Auro Laboratories Limited is audited by M/s. B L Dasharda & Associates (ICAI peer reviewed, certificate valid till 2028-03-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s. B L Dasharda & Associates (ICAI peer reviewed, certificate valid till 2028-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Auro Laboratories Limited

Auro Laboratories Limited is currently managed by 7 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Kiran Suresh Kulkarni Whole-Time Director 24 May 2021 5 Years 1 Months Current
Mahendra Kumar Daga Director 01 Apr 2024 2 Years 3 Months Current
Siddhartha Deorah
Also directs: Auro Impex Pvt Ltd
Whole-Time Director 16 Dec 2013 12 Years 6 Months Current
Vishal Kailashchandra Jhunjhunwala
Also directs: Aava Wealth Llp, Vista Business Ventures Llp, Sj Ecotech Llp and 5 more
Director 23 Aug 2023 2 Years 10 Months Current
Sharat Deorah
Also directs: Auro Impex Pvt Ltd
Managing Director 26 May 1989 37 Years 1 Months Current
Kavita Vijayakant Sharma Director 27 Mar 2015 11 Years 3 Months Current
Showing 6 of 7 current directors. View all directors

Financials of Auro Laboratories Limited FY 2026 filings available

Auro Laboratories Limited reported revenue of ₹30.74 Cr (up 58.47% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹30.74 Cr ▲ 58.47%
Profit · FY 2026
₹3.53 Cr ▲ 92.13%
EBITDA · FY 2026
₹12.02 Cr ▲ 195.98%
Revenue₹ Cr · Standalone0204060FY 2019: ₹47 Cr46.8FY 2019FY 2020: ₹44 Cr · -6.5% YoY43.8-6.5%FY 2020FY 2021: ₹54 Cr · +23.9% YoY54.3+23.9%FY 2021FY 2022: ₹51 Cr · -6.2% YoY50.9-6.2%FY 2022FY 2023: ₹53 Cr · +4% YoY52.9+4%FY 2023FY 2024: ₹54 Cr · +1.4% YoY53.6+1.4%FY 2024FY 2025: ₹19 Cr · -63.8% YoY19.4-63.8%FY 2025FY 2026: ₹31 Cr · +58.5% YoY30.7+58.5%FY 2026
Net Profit₹ Cr · Standalone0510FY 2019: ₹4 Cr4.4FY 2019FY 2020: ₹4 Cr · -7.8% YoY4.1-7.8%FY 2020FY 2021: ₹7 Cr · +77.1% YoY7.2+77.1%FY 2021FY 2022: ₹3 Cr · -60.4% YoY2.8-60.4%FY 2022FY 2023: ₹2 Cr · -14.2% YoY2.4-14.2%FY 2023FY 2024: ₹8 Cr · +219.1% YoY7.8+219.1%FY 2024FY 2025: ₹2 Cr · -76.4% YoY1.8-76.4%FY 2025FY 2026: ₹4 Cr · +92.1% YoY3.5+92.1%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0510Q1'25: ₹6 Cr5.7Q1'25Q2'25: ₹3 Cr3.1Q2'25Q3'25: ₹3 Cr3.1Q3'25Q4'25: ₹7 Cr7.4Q4'25Q1'26: ₹3 Cr · -51.5% YoY2.8-51.5%Q1'26Q2'26: ₹9 Cr · +184.9% YoY8.8+184.9%Q2'26Q3'26: ₹9 Cr · +207.5% YoY9.4+207.5%Q3'26Q4'26: ₹10 Cr · +32.9% YoY9.8+32.9%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹30.74 Cr ₹19.4 Cr ₹53.64 Cr ₹52.89 Cr ₹50.87 Cr ₹54.25 Cr ₹43.79 Cr ₹46.82 Cr
Other Income ₹2.01 Cr ₹65.5 Lakh ₹1.5 Cr ₹94.13 Lakh ₹1.09 Cr ₹75.78 Lakh ₹97.26 Lakh ₹95.82 Lakh
Total Income ₹32.75 Cr ₹20.05 Cr ₹55.14 Cr ₹53.84 Cr ₹51.96 Cr ₹55.01 Cr ₹44.76 Cr ₹47.78 Cr
Cost of Materials Consumed ₹14.28 Cr ₹5.06 Cr ₹29.04 Cr ₹37.3 Cr ₹33.74 Cr ₹27.43 Cr ₹23.42 Cr ₹30.14 Cr
Purchases of Stock-in-Trade ₹1.43 Lakh ₹1.64 Lakh ₹0 ₹0 ₹2.4 Lakh ₹21.03 Lakh ₹56.61 Lakh ₹24.91 Lakh
Changes in Inventories -₹8.23 Cr ₹4.13 Cr -₹2.48 Cr -₹1.61 Cr -₹98.16 Lakh ₹90.71 Lakh ₹49.18 Lakh -₹1.77 Cr
Employee Benefit Expense ₹5.86 Cr ₹2.47 Cr ₹5.14 Cr ₹4.72 Cr ₹6.24 Cr ₹6.04 Cr ₹5.28 Cr ₹4.07 Cr
Finance Costs ₹4.25 Cr ₹1.08 Cr ₹73.57 Lakh ₹81.42 Lakh ₹82.64 Lakh ₹45.83 Lakh ₹46.63 Lakh ₹72.22 Lakh
Depreciation & Amortisation ₹2.81 Cr ₹1.1 Cr ₹1.09 Cr ₹1.07 Cr ₹1.02 Cr ₹1.04 Cr ₹1.02 Cr ₹1.01 Cr
Other Expenses ₹8.81 Cr ₹4.32 Cr ₹11.26 Cr ₹8.08 Cr ₹7.22 Cr ₹8.43 Cr ₹7.88 Cr ₹7.29 Cr
Total Expenses ₹27.8 Cr ₹18.17 Cr ₹44.79 Cr ₹50.39 Cr ₹48.08 Cr ₹44.5 Cr ₹39.12 Cr ₹41.71 Cr
Profit Before Exceptional Items & Tax ₹4.95 Cr ₹1.88 Cr ₹10.35 Cr ₹3.45 Cr ₹3.87 Cr ₹10.51 Cr ₹5.64 Cr ₹6.07 Cr
Exceptional Items -₹14.42 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹4.81 Cr ₹1.88 Cr ₹10.35 Cr ₹3.45 Cr ₹3.87 Cr ₹10.51 Cr ₹5.64 Cr ₹6.07 Cr
Total Tax Expense ₹1.28 Cr ₹4.21 Lakh ₹2.55 Cr ₹1 Cr ₹1.03 Cr ₹3.33 Cr ₹1.59 Cr ₹1.67 Cr
Net Profit ₹3.53 Cr ₹1.84 Cr ₹7.79 Cr ₹2.44 Cr ₹2.84 Cr ₹7.18 Cr ₹4.05 Cr ₹4.4 Cr
Other Comprehensive Income -₹15.34 Lakh ₹11.62 Lakh ₹32.13 Lakh ₹35.26 Lakh ₹11.14 Lakh ₹1.76 Lakh ₹11.22 Lakh ₹8.11 Lakh
Total Comprehensive Income ₹3.38 Cr ₹1.96 Cr ₹8.11 Cr ₹2.79 Cr ₹2.96 Cr ₹7.2 Cr ₹4.17 Cr ₹4.48 Cr
EBITDA (computed) ₹12.02 Cr ₹4.06 Cr ₹12.17 Cr ₹5.33 Cr ₹5.72 Cr ₹12 Cr ₹7.13 Cr ₹7.8 Cr
Basic EPS ₹5.67 ₹2.95 ₹12.50 ₹3.92 ₹4.56 ₹11.52 ₹6.51 ₹7.06
Diluted EPS ₹5.67 ₹2.95 ₹12.50 ₹3.92 ₹4.56 ₹11.52 ₹6.51 ₹7.06
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹121.08 Cr ₹99.1 Cr ₹85.73 Cr ₹55.99 Cr ₹54.96 Cr ₹41.89 Cr ₹32.35 Cr ₹33.47 Cr
Non-current Assets ₹90.32 Cr ₹77.58 Cr ₹54.88 Cr ₹20.33 Cr ₹17.33 Cr ₹13.74 Cr ₹14.4 Cr ₹23.25 Cr
Current Assets ₹30.76 Cr ₹21.51 Cr ₹30.85 Cr ₹35.66 Cr ₹37.63 Cr ₹28.15 Cr ₹17.95 Cr ₹10.21 Cr
Property, Plant & Equipment ₹75.18 Cr ₹21.06 Cr ₹22.15 Cr ₹12.62 Cr ₹13.61 Cr ₹13.56 Cr ₹14.24 Cr ₹14.59 Cr
Inventories ₹13.54 Cr ₹3.67 Cr ₹8.24 Cr ₹11.76 Cr ₹4.25 Cr ₹2.55 Cr ₹4.06 Cr ₹3.37 Cr
Trade Receivables ₹9.15 Cr ₹9.39 Cr ₹13.39 Cr ₹12.4 Cr ₹13.61 Cr ₹7.3 Cr ₹5.78 Cr ₹0
Cash & Equivalents ₹1.37 Cr ₹3,000 ₹99.22 Lakh ₹1.79 Cr ₹5.21 Cr ₹10.82 Cr ₹5.03 Cr ₹3.36 Cr
Equity (Net Worth) ₹46.35 Cr ₹42.97 Cr ₹41.96 Cr ₹34.2 Cr ₹31.52 Cr ₹28.58 Cr ₹21.5 Cr ₹17.41 Cr
Equity Share Capital ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr ₹6.23 Cr
Borrowings (Non-current) ₹43.31 Cr ₹33.09 Cr ₹18.38 Cr ₹1.76 Cr ₹84.95 Lakh ₹2.04 Cr ₹1.81 Cr ₹6.15 Cr
Borrowings (Current) ₹19.99 Cr ₹11.93 Cr ₹7.87 Cr ₹4.4 Cr ₹12.12 Cr ₹0 ₹0 ₹0
Total Debt (computed) ₹63.31 Cr ₹45.01 Cr ₹26.24 Cr ₹6.16 Cr ₹12.97 Cr ₹2.04 Cr ₹1.81 Cr ₹6.15 Cr
Current Liabilities ₹28.55 Cr ₹21.64 Cr ₹23.93 Cr ₹18.13 Cr ₹20.13 Cr ₹8.47 Cr ₹6.14 Cr ₹6.46 Cr
Total Liabilities ₹74.74 Cr ₹56.13 Cr ₹43.77 Cr ₹21.79 Cr ₹23.44 Cr ₹13.31 Cr ₹10.85 Cr ₹16.05 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹2.11 Cr ₹5.75 Cr ₹18.81 Cr ₹3.28 Cr -₹6.59 Cr
Investing Cash Flow -₹14.78 Cr -₹24.45 Cr -₹38.67 Cr -₹5.08 Cr -₹5.34 Cr
Financing Cash Flow ₹14.04 Cr ₹17.69 Cr ₹19.09 Cr -₹8.18 Cr ₹9.79 Cr
Capital Expenditure ₹57.14 Cr ₹23.8 Cr ₹35.64 Cr ₹4.07 Cr ₹4.61 Cr
Free Cash Flow (computed) -₹55.03 Cr -₹18.05 Cr -₹16.83 Cr -₹79.31 Lakh -₹11.2 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹1.37 Cr -₹1.02 Cr -₹76.82 Lakh -₹9.98 Cr -₹2.14 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹9.83 Cr ₹9.39 Cr ₹8.84 Cr ₹2.77 Cr ₹7.4 Cr ₹3.05 Cr ₹3.1 Cr ₹5.72 Cr
Other Income ₹66.38 Lakh ₹17.73 Lakh ₹97.58 Lakh ₹41.65 Lakh ₹12.94 Lakh ₹14.09 Lakh ₹30.79 Lakh ₹20.28 Lakh
Total Income ₹10.5 Cr ₹9.57 Cr ₹9.81 Cr ₹3.19 Cr ₹7.53 Cr ₹3.2 Cr ₹3.41 Cr ₹5.92 Cr
Cost of Materials Consumed ₹3.73 Cr ₹3.12 Cr ₹6.15 Cr ₹1.25 Cr ₹3.34 Cr ₹1.18 Cr -₹7.91 Lakh ₹64.87 Lakh
Purchases of Stock-in-Trade ₹0 ₹0 ₹1.43 Lakh ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹1.69 Cr -₹2 Cr -₹4.2 Cr -₹34.77 Lakh ₹1.79 Cr ₹1.1 Cr ₹13.49 Lakh ₹1.1 Cr
Employee Benefit Expense ₹2 Cr ₹1.59 Cr ₹1.45 Cr ₹49.11 Lakh ₹63.8 Lakh ₹3.4 Lakh ₹1.05 Cr ₹1.09 Cr
Finance Costs ₹1.49 Cr ₹1.52 Cr ₹96.23 Lakh ₹28.07 Lakh ₹30.44 Lakh ₹24.57 Lakh ₹28.23 Lakh ₹25.01 Lakh
Depreciation & Amortisation ₹90.35 Lakh ₹98.18 Lakh ₹65.08 Lakh ₹27.41 Lakh ₹28.62 Lakh ₹27 Lakh ₹27 Lakh ₹27 Lakh
Other Expenses ₹2.47 Cr ₹2.62 Cr ₹3.06 Cr ₹1.35 Cr ₹81.27 Lakh ₹29.37 Lakh ₹1.27 Cr ₹1.56 Cr
Total Expenses ₹8.9 Cr ₹7.83 Cr ₹8.09 Cr ₹3.3 Cr ₹7.18 Cr ₹3.13 Cr ₹2.93 Cr ₹4.92 Cr
Profit Before Exceptional Items & Tax ₹1.6 Cr ₹1.74 Cr ₹1.72 Cr -₹10.54 Lakh ₹35.24 Lakh ₹6.82 Lakh ₹47.86 Lakh ₹1.01 Cr
Exceptional Items -₹14.42 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹1.46 Cr ₹1.74 Cr ₹1.72 Cr -₹10.54 Lakh ₹35.24 Lakh ₹6.82 Lakh ₹47.86 Lakh ₹1.01 Cr
Total Tax Expense ₹48.46 Lakh -₹21.34 Lakh ₹1 Cr ₹0 -₹4.17 Lakh ₹1.71 Lakh ₹12.04 Lakh ₹25.32 Lakh
Net Profit ₹97.06 Lakh ₹1.95 Cr ₹71.57 Lakh -₹10.54 Lakh ₹39.41 Lakh ₹5.11 Lakh ₹35.82 Lakh ₹75.26 Lakh
Other Comprehensive Income -₹11,000 -₹15.23 Lakh -₹33.52 Lakh ₹33.52 Lakh ₹11.62 Lakh ₹3.78 Lakh ₹29.79 Lakh ₹23.29 Lakh
Total Comprehensive Income ₹96.95 Lakh ₹1.8 Cr ₹38.05 Lakh ₹22.98 Lakh ₹51.03 Lakh ₹8.89 Lakh ₹65.61 Lakh ₹98.55 Lakh
EBITDA (computed) ₹3.99 Cr ₹4.24 Cr ₹3.33 Cr ₹44.94 Lakh ₹94.3 Lakh ₹58.39 Lakh ₹1.03 Cr ₹1.53 Cr
Basic EPS ₹1.56 ₹3.13 ₹1.15 ₹-0.17 ₹0.63 ₹0.08 ₹0.57 ₹1.21
Diluted EPS ₹1.56 ₹3.13 ₹1.15 ₹-0.17 ₹0.63 ₹0.08 ₹0.57 ₹1.21
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Auro Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Auro Laboratories Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 52.18%, domestic institutional investors hold 0.01%, retail and other public shareholders hold 47.82% of Auro Laboratories Limited. The company had 8,405 shareholders on record.

Promoters: 52.18%DII (Domestic Institutional): 0.01%Retail & Others: 47.82%
Mar 2026
QUARTER
52.18% Promoters
0.01% DII (Domestic Institutional)
47.82% Retail & Others
Promoter holding - history
Now 52.18% · Mar 2026High 52.18% · Mar 2025Low 52.09% · Jun 2023
51%51.8%52.5%53.3%54%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 52.09%Sep 2023: 52.09%Dec 2023: 52.09%Mar 2024: 52.15%Jun 2024: 52.15%Sep 2024: 52.15%Dec 2024: 52.15%Mar 2025: 52.18%Jun 2025: 52.18%Sep 2025: 52.18%Dec 2025: 52.18%Mar 2026: 52.18%52.18%52.09%52.18%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters52.18%52.18%52.18%52.18%52.18%52.15%
Public47.82%47.82%47.82%47.82%47.82%47.85%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters52.18%52.18%52.15%
Public47.82%47.82%47.85%
Promoter change (YoY, %pts)+0.00+0.03-

Charges & Borrowings of Auro Laboratories Limited

Open charges
₹68 Cr
Satisfied charges
₹11.97 Cr
Breakdown by lending institutions
Indian Bank₹68.00 Cr
Latest charge details
DateLenderAmountStatus
29 Feb 2024 Indian Bank ₹20 Lakh Open
20 Dec 2002 Indian Bank ₹67.8 Cr Open
21 Jul 2025 Indian Bank ₹1.8 Cr Satisfied
21 Mar 2025 Indian Bank ₹1.8 Cr Satisfied
26 Apr 2012 Allahabad Bank ₹1 Cr Satisfied

Total charge records: 15 View all charges

Employees and EPFO Compliance at Auro Laboratories Limited

View historical data on people associated with Auro Laboratories Limited, including employment history and EPFO contributions.

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Auro Laboratories Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Auro Laboratories Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Auro Laboratories Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Auro Laboratories Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Auro Laboratories Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Auro Laboratories Limited

MSME Payment Delays by Auro Laboratories Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Auro Laboratories Limited

Subsidiaries & Group Companies of Auro Laboratories Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Auro Laboratories Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Auro Laboratories Limited

MCA Filings & Documents of Auro Laboratories Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Auro Laboratories Limited

Charges
19 Nov 2025
A charge registered on 21 Jul 2025 via Charge ID 101138770 with Indian Bank was fully satisfied on 19 Nov 2025.
Charges
04 Nov 2025
A charge with Indian Bank of Rs. 67.80 Cr registered on 20 Dec 2002 with Charge ID 90240936 was modified on 04 Nov 2025.
Activity
25 Sep 2025
Auro Laboratories Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
11 Aug 2025
A charge registered on 21 Mar 2025 via Charge ID 101077650 with Indian Bank was fully satisfied on 11 Aug 2025.
Charges
21 Jul 2025
A charge with Indian Bank amounted to Rs. 1.80 Cr with Charge ID 101138770 was registered on 21 Jul 2025.
Directors
12 Jun 2025
Kuntal Prafulchandra Pancholi was appointed as a Cfo on 12 Jun 2025 & has been associated with this company since 1 year 27 days.

Frequently Asked Questions about Auro Laboratories Limited

Auro Laboratories Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 26 May 1989 (37+ years old) and is registered under CIN L33125MH1989PLC051910. Listed on BSE: 530233.

Auro Laboratories Limited reported revenue of ₹20.05 Cr for FY 2025 (down 64.00% YoY).

The current directors of Auro Laboratories Limited are:

The primary industry of Auro Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Auro Laboratories Limited is listed on BSE with code 530233.

Auro Laboratories Limited can be reached at the registered office: K – 56 M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506, or through the website aurolabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available